Results 41 to 50 of about 51,890 (248)

An unusual case of multiple myeloma [PDF]

, 2013
The case concerns the unusual presentation of a non-secretory multiple myeloma with diarrhoea secondary to large bowel infiltration. In December 2009, a 74-year-old lady presented to hospital and complained of a two year history of intermittent ...
Delicata, Julian, Farrugia, Daniel
core  

Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids

FEBS Open Bio, EarlyView.
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão, Diogo M. Engrácia, Graça Soveral, Filipa Mendes   +3 more
wiley   +1 more source

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics

Blood Cancer Journal, 2023
Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed.
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia   +14 more
doaj   +1 more source

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival

, 2011
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
Hatton, CSR, Taylor Steve, Taylor, Stephen, Taylor, S, Lawrie Charles H, Saunders, NJ, Steve Taylor, Pezzella Francesco, Saunders Nigel J, Tramonti, D, Lawrie, CH, Wainscoat James S, Kusec, R, Pezzella, F, Tramonti Daniela, Nigel J Saunders, Hatton Christian SR, Chen, XH, Hatton, CS, Charles H Lawrie, Rajko Kušec, Littlewood, T, Erica Ballabio, Deborah Hay, Timothy Littlewood, Chi, J, Jacqueline Boultwood, Boultwood Jacqueline, Kušec Rajko, Jianxiang Chi, Chen Xiao-He, James S Wainscoat, Ballabio, E, Ballabio Erica, Chi Jianxiang, Xiao-He Chen, Littlewood Timothy, Francesco Pezzella, Christian SR Hatton, Wainscoat, JS, Hay Deborah, Pezzella, Francesco, Boultwood, Jacqueline, Hay, D, Boultwood, J, Daniela Tramonti   +45 more
core   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period

Blood Cancer Journal
The treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies and optimized supportive care. However, the attrition rate (AR), defined as the proportion of patients who die without advancing to ...
Luis Gerardo Rodríguez-Lobato, Anna de Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Jose Miguel Mateos, Noemí Llobet, Esther Carcelero, Daniel Munárriz, Joan Bladé, Laura Rosiñol   +12 more
doaj   +1 more source

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Frontiers in Oncology, 2021
Multiple myeloma (MM) is an incurable malignancy of plasma cells that grow within a permissive bone marrow microenvironment (BMM). The bone marrow milieu supports the malignant transformation both by promoting uncontrolled proliferation and resistance to
Leona Yamamoto, Nicola Amodio, Annamaria Gulla, Kenneth Carl Anderson   +3 more
doaj   +1 more source

Multiple myeloma

Nature Reviews Disease Primers
Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence.
Florent Malard, Paola Neri, Nizar J. Bahlis, Evangelos Terpos, Nour Moukalled, Vania T. M. Hungria, Salomon Manier, Mohamad Mohty   +7 more
openaire   +3 more sources

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Frontiers in Immunology, 2018
Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years.
Yu-Tzu Tai, Shih-Feng Cho, Shih-Feng Cho, Shih-Feng Cho, Kenneth C. Anderson   +4 more
doaj   +1 more source